Pediatric leukemia patients in the EU have moved a step forward to access broader treatment options. The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending expansion of the marketing authorization for Besponsa (inotuzumab ozogamicin, Pfizer Europe) to include children aged 1 year or older. 

Under the proposed label change, Besponsa would be indicated as monotherapy for pediatric patients 1 year or older with CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first relapse after allogeneic hematopoietic stem cell transplant, after any first relapse in patients with very high-risk disease, after a second or greater relapse, and in refractory disease. Patients with Philadelphia chromosome-positive disease should have exhausted relevant BCR-ABL-targeting treatment options.

ALL is the most common childhood cancer, affecting roughly 40 children per million annually in Western Europe among those younger than 15 years. While modern treatment protocols cure more than 85% of children with newly diagnosed ALL, approximately 15% experience relapse or demonstrate resistance to conventional therapy. CD22 appears on approximately 90% of childhood B-cell precursor ALL cases, making it an attractive therapeutic target. For patients whose disease has returned or in whom initial treatments have vailed, the prognosis remains poor, with only about 50% achieving rescue through intensive chemotherapy followed by stem cell transplantation in high-risk situations.

Drug Mechanism and Clinical Evidence 

Besponsa functions as a CD22-directed monoclonal antibody covalently linked to a cytotoxic agent, N-acetyl-gamma-calicheamicin dimethylhydrazide. The therapeutic agent specifically recognizes human CD22 protein expressed on cancerous B cells. Following cellular binding and internalization, the cytotoxic payload becomes active through hydrolytic cleavage, inducing double-stranded DNA breaks that trigger cell cycle arrest and programmed cell death.

The CHMP’s positive opinion relied on final results from two key studies: ITCC-059 and INOPed-ALL-1. ITCC-059 was a phase 1/2 trial evaluating the effects of inotuzumab ozogamicin in 53 pediatric patients aged 1-18 years with relapsed or refractory CD22-positive ALL. In the phase 1 cohort of 25 patients, investigators achieved an 80% objective response rate with a median duration of response of 8.0 months. The phase 2 cohort of 28 patients demonstrated a 79% objective response rate with a median duration of response of 7.6 months. Among responding patients, 84% achieved minimal residual disease-negative complete remission.

Pharmacologic analysis demonstrated that pediatric patients achieved drug concentrations comparable to those in adults receiving the same dose intensity. Peak concentrations at the recommended dose level reached 246 ng/mL in children, closely matching simulated adult levels of 234 ng/mL. 

The recommended dosing regimen for both pediatric and adult patients involves a cycle-based approach with 1.8 mg/m² per course for the initial cycle, administered as three divided doses on days 1, 8, and 15. Subsequent cycles use either 1.5 mg/m² or 1.8 mg/m² depending on patient response, with treatments given every 3-4 weeks.

Safety Profile and Clinical Implementation 

Both pediatric and adult studies demonstrated manageable safety profiles, and most adverse events were expected for this patient population. Common side effects included thrombocytopenia, pyrexia, anemia, vomiting, neutropenia, and infection. Hepatic veno-occlusive disease was a less common but serious concern and requires careful monitoring for symptoms including rapid weight gain, abdominal pain, liver enlargement, and elevated bilirubin levels.

Healthcare providers must monitor patients for several serious adverse effects during treatment, including QT interval prolongation that can cause serious heart rhythm abnormalities. Regular electrocardiograms and electrolyte monitoring help detect these changes early. Patients require premedication with corticosteroids, antipyretics, and antihistamines to reduce infusion-related reactions. 

Detailed recommendations for using this product will be described in the updated summary of product characteristics, which will be published on the EMA website in all official EU languages after the European Commission grants a decision on this marketing authorization change.